Non-alcoholic fatty liver disease concerns with glucokinase activators
We read with interest the Article in The Lancet Diabetes and Endocrinology by Dalong Zhu and colleagues, in which dorzagliatin, a dual-acting, allosteric glucokinase activator, showed a beneficial effect on glycaemic control in a phase 2 trial. Although the introduction of a new class of glucose-low...
Main Authors: | Hodson, L, Brouwers, M |
---|---|
Format: | Journal article |
Published: |
Elsevier
2018
|
Similar Items
-
Association of glucokinase regulatory gene polymorphisms with
risk and severity of non-alcoholic fatty liver disease: An interaction study with adiponutrin gene
by: Cheah, Phaik Leng, et al.
Published: (2013) -
The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD)
by: Savic, D, et al.
Published: (2020) -
The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Dragana Savic, et al.
Published: (2020-07-01) -
Non-alcoholic fatty liver disease
by: Pavlides, M, et al.
Published: (2019) -
Non-alcoholic fatty liver disease in adults: Current concepts in etiology, outcomes and management
by: Marjot, T, et al.
Published: (2019)